RESET REALITY

## John's Story

As a college freshman, John had many educational and career goals ahead of him. The future was full of opportunities, but instead of getting an education and growing into an independent adult, he fell to the mercy of addiction.

John threw his back out while lifting weights and was prescribed opioid prescription painkillers to help with the pain. He became hooked on the medication, and for the next four years he readily accessed painkillers through walk-in clinics.

After college, John moved back in with his parents. His opioid dependence took precedence over nearly everything else in his life. John invested most of his time in seeking out his next fix and began to lose touch with himself, and his family. He was not able to reach the educational or financial goals he once had for himself and his physical and mental health were fading. John's mother was so troubled by his behavior that she eventually moved out of her own house.

At that moment, John made a decision to reset his reality. He and his dad researched treatment facilities and John began a treatment plan, which now includes SUBOXONE® (buprenorphine and naloxone) Sublingual Film and counseling. He has rebuilt relationships with his family and now can take part in the activities he enjoys. He has even decided to pursue a career as a counselor to offer his support to others who are battling addiction.

As a Reset Reality ambassador, John wants others to know that while there may not be a cure, prescription painkiller addiction can be managed much more easily with the right tools and a treatment plan. He is sharing his story to show others that addiction does not have to stand in the way of a successful life.

### Indication

SUBOXONE® (buprenorphine and naloxone) Sublingual Film is indicated for maintenance treatment of opioid dependence as part of a complete treatment plan to include counseling and psychosocial support.

Treatment should be initiated under the direction of physicians qualified under the Drug Addiction Treatment Act.

### Important Safety Information

SUBOXONE® (buprenorphine and naloxone) Sublingual Film should not be used by patients hypersensitive to buprenorphine or naloxone, as serious adverse reactions, including anaphylactic shock, have been reported.

RESET REALITY

**Important Safety Information (cont'd)**

SUBOXONE (buprenorphine and naloxone) Sublingual Film can be abused in a manner similar to other opioids, legal or illicit. Clinical monitoring appropriate to the patient's level of stability is essential.

Chronic use of buprenorphine can cause physical dependence. A sudden or rapid decrease in dose may result in an opioid withdrawal syndrome that is typically milder than seen with full agonists and may be delayed in onset.

SUBOXONE Sublingual Film can cause serious life-threatening respiratory depression and death, particularly when taken by the intravenous (IV) route in combination with benzodiazepines or other central nervous system (CNS) depressants (ie, sedatives, tranquilizers, or alcohol). It is extremely dangerous to self-administer nonprescribed benzodiazepines or other CNS depressants while taking SUBOXONE Sublingual Film. Dose reduction of CNS depressants, SUBOXONE Sublingual Film, or both when both are being taken should be considered.

Liver function should be monitored before and during treatment.

Death has been reported in nontolerant, nondependent individuals, especially in the presence of CNS depressants.

Children who take SUBOXONE Sublingual Film can have severe, possibly fatal, respiratory depression. Emergency medical care is critical. Keep SUBOXONE Sublingual Film out of the sight and reach of children.

Intravenous misuse or taking SUBOXONE Sublingual Film before the effects of full-agonist opioids (eg, heroin, hydrocodone, methadone, morphine, oxycodone) have subsided is highly likely to cause opioid withdrawal symptoms.

Neonatal withdrawal has been reported.

Use of SUBOXONE Sublingual Film in pregnant women or during breast-feeding should only be considered if the potential benefit justifies the potential risk.

Caution should be exercised when driving vehicles or operating hazardous machinery, especially during dose adjustment.

Adverse events commonly observed with the sublingual administration of SUBOXONE Sublingual Film are oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting, hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.

Cytolytic hepatitis, jaundice, and allergic reactions, including anaphylactic shock, have been reported.

This is not a complete list of potential adverse events associated with SUBOXONE Sublingual Film. Please see full Prescribing Information for a complete list at www.suboxone.com/pdfs/SuboxonePI.pdf.

RESET REALITY

**Important Safety Information (cont'd)**

To report an adverse event associated with taking SUBOXONE (buprenorphine and naloxone) Sublingual Film, pleasecall 1-877-782-6966. You are encouraged to report adverse events of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

# # #